Ebit تغيير تاريخ
Alnylam Pharmaceuticals USD 137.59M 108.19M 2026-03
BioCryst Pharmaceuticals USD 260.38M 230.79M 2025-12
Chugai Pharma JPY 158.77B 10.24B 2026-03
Daiichi Sankyo JPY 89.54B 42.01B 2025-12
DBV Technologies USD -34.28M 6.83M 2025-09
Enanta Pharmaceuticals USD -23.54M 6.31M 2024-12
Gilead Sciences USD 2.68B 284M 2026-03
GlaxoSmithKline GBP 2.29B 856M 2026-03
Glaxosmithkline GBP 2.3B 1.46B 2025-12
Incyte USD 344.17M 39.71M 2026-03
Ionis Pharmaceuticals USD -118M 97M 2026-03
Karyopharm Therapeutics USD -17.84M 8.44M 2025-12
Neurocrine Biosciences USD 214.6M 13.3M 2026-03
Novavax USD 20.94M 100.32M 2025-12
PTC Therapeutics USD 45.89M 127.51M 2026-03
Regeneron Pharmaceuticals USD 744.8M 153.8M 2026-03
Roche Holding CHF 9.56B 2.1B 2025-12
Sarepta Therapeutics USD 358.43M 768.52M 2026-03
Ultragenyx Pharmaceutical USD -216M 102M 2026-03
Vertex Pharmaceuticals USD 1.14B 124.5M 2026-03